Galectin-3 and fibulin-1 in systolic heart failure patients with and without diabetes: relation to glucose metabolism and left ventricular contractile reserve

Pernille Holmager; Michael Egstrup; Ida Gustafsson; Morten Schou; Jordi Dahl; Lars Melholt Ramussen; Jacob Moller; Christian Tuxen; Jens Faber; Caroline Kistorp

doi:10.1530/endoabs.37.EP560

EP560

Prev Next

Section Contents Cite

Endocrine Abstracts (2015) 37 EP560 | DOI: 10.1530/endoabs.37.EP560

ECE2015 Eposter Presentations Obesity and cardiovascular endocrinology (108 abstracts)

Galectin-3 and fibulin-1 in systolic heart failure patients with and without diabetes: relation to glucose metabolism and left ventricular contractile reserve

Pernille Holmager ¹ , Michael Egstrup ² , Ida Gustafsson ³ , Morten Schou ⁴ , Jordi Dahl ⁵ , Lars Melholt Ramussen ⁶ , Jacob Møller ⁵ , Christian Tuxen ⁷ , Jens Faber ^1, & Caroline Kistorp ^1,

Err

Author affiliations View ePoster Download ePoster

¹Department of Medicine, Herlev University Hospital, Herlev, Denmark; ²Department of Cardiology, Rigshospitalet, Copenhagen, Denmark; ³Department of Cardiology, Hvidovre University Hospital, Hvidovre, Denmark; ⁴Department of Cardiology, Herlev University Hospital, Herlev, Denmark; ⁵Department of Cardiology, Odense Univeristy Hospital, Odense, Denmark; ⁶Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark; ⁷Department of Cardiology, Bispebjerg Hospital, Copenhagen, Denmark; ⁸Faculty of Health and Science, Copenhagen University, Copenhagen, Denmark.

Aims: Diabetic patients with heart failure (HF) have an adverse prognosis, which could be linked with reduced left ventricular (LV) contractile reserve. Galectin-3 (Gal-3) and fibulin-1 are potential biomarkers of fibrosis. The aims were to evaluate the impact of DM on Gal-3 and fibulin-1 levels and the association to LV contractile reserve in HF patients with and without diabetes (DM).

Methods and results: From an out-patient HF clinic 155 patients with systolic HF were included and underwent a low-dose dobutamine echocardiography and blood sampling for analyses of plasma Gal-3 and fibulin levels. Oral glucose tolerance test (OGTT) was performed in non-diabetic HF patients. Based on history of DM and OGTT patients were divided into normal glucose tolerance (NGT) (n=95), impaired glucose tolerance (IGT) (n=25), and DM (n=60).

Results: Galectin-3 levels were 17.9 ng/ml in diabetics (P=0.02) while fibulin-1 levels were not influenced by DM status. Gal-3 was associated with LV contractile reserve in a univariable regression model; standardized β (S.E.M.) (β=−0.19, P=0.03), but not in a multivariable model including eGFR, (β=−0.04, P=0.66). Fibulin-1 was not associated with LV contractile reserve in a univariable model (β=−0.06, P=0.51). HbA1c was independently associated with Gal-3 (β=0.16, P=0.02) and fibulin-1 (β=0.16, P=0.04) in a multivariable regression model including eGFR.